Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Применение метформина в настоящем и будущем
Применение метформина в настоящем и будущем
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Полный текст
Список литературы
1. Lefebvre P. Metformin. The Gold Standard. A Scientific Handbook. Ed. Bailey CJ, Campbell JW, Chan JCN. Wiley. 2007. P1.
2. De Fronzo R.A. idem. P. 37.
3. Campbell IW, Ritz P. idem P.77–88.
4. Muller S, Denet S, Candiloros H, Action of metformin on erythrocyte membrane fluidity in vitro and in vivo. Eur J Pharmacol, 1997; 337: 103–10.
5. Jonson AB, Webster JM, SUM CF. The impact of metformin therapy on hepatic glucose production and sceletal muscule glycogen synthase activity in overweight type 2 diabetes patients. Metabolism 1993, 42: 1217–22.
6. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T. Effect of Rosiglitazone and Metformin on liver fat content, hepatic insulin resistance,insulin clearancew, and gen expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53: 2169–76.
7. Scarpello JH. Improving survival with metformin: the evidence base to day. Diabet Metabol 2003, 29: 6S36–43.
8. Bailey CJ, Howlett HCS. Defining patient populations not indicated for metformin. Metformin. The Gold Standard. A Scientific Handbook. Ed. Bailey CJ, Campbell JW, Chan JCN. Wiley. 2007; 193–8.
9. Emsley-Smith AM, Boyle DI, Evance JM et al. Contraindication to metformin therapy in patients with type 2 diabetes – a population-based study of adherence to prescribing quidelines. Diabet Med 2003; 18: 483–8.
10. Stacpoole PW, Wright EC, Baumgarten TG. Natural history and course of acquired lactic acidosis in adult. DCA-Lactic Acidosis Study Groop. Am J Med 1992; 97: 47–54.
11. Eurich DT, Majumdar SR, Mc Alister FA et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabet Care 2005; 28: 2345–51.
12. Mc Donald A, Eurich DT, Mayumidar SR.Treatment of type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case-Control Study From UK General Practice Research Datebase. Diabet Care 2010; 33: 1210–9.
13. Bowker SL, Veugelers P. Majumdar SR, Jonson JA. Increased Cancer-Related Mortalitt for Patients With Type 2 Diabetes Who Use Sulfanilureas or Insulin. Diabet Care 2006; 29: 254–8.
14. Currie CJ, Pool CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetology DOI:10. 1007/ s00125–009–1440–6.
15. Landman GWG, Kleefstra N, Van Haleren KJJ. Metformin associated with Lower Cancer Mortality in Type 2 Diabetes. Diabet Care 2010; 33: 322–6.
16. Берштейн Л.М. Гиполипидемические и антидиабетические препараты как средство предупреждения и терапии злокачественных опухолей: клинические данные. НИИ онкологии им. проф. Н.Н.Петрова МЗ РФ, Санкт-Петербург. Сборник тезисов VIII Российского онкологического конгресса. М., 22–24 ноября 2004 г.
2. De Fronzo R.A. idem. P. 37.
3. Campbell IW, Ritz P. idem P.77–88.
4. Muller S, Denet S, Candiloros H, Action of metformin on erythrocyte membrane fluidity in vitro and in vivo. Eur J Pharmacol, 1997; 337: 103–10.
5. Jonson AB, Webster JM, SUM CF. The impact of metformin therapy on hepatic glucose production and sceletal muscule glycogen synthase activity in overweight type 2 diabetes patients. Metabolism 1993, 42: 1217–22.
6. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T. Effect of Rosiglitazone and Metformin on liver fat content, hepatic insulin resistance,insulin clearancew, and gen expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53: 2169–76.
7. Scarpello JH. Improving survival with metformin: the evidence base to day. Diabet Metabol 2003, 29: 6S36–43.
8. Bailey CJ, Howlett HCS. Defining patient populations not indicated for metformin. Metformin. The Gold Standard. A Scientific Handbook. Ed. Bailey CJ, Campbell JW, Chan JCN. Wiley. 2007; 193–8.
9. Emsley-Smith AM, Boyle DI, Evance JM et al. Contraindication to metformin therapy in patients with type 2 diabetes – a population-based study of adherence to prescribing quidelines. Diabet Med 2003; 18: 483–8.
10. Stacpoole PW, Wright EC, Baumgarten TG. Natural history and course of acquired lactic acidosis in adult. DCA-Lactic Acidosis Study Groop. Am J Med 1992; 97: 47–54.
11. Eurich DT, Majumdar SR, Mc Alister FA et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabet Care 2005; 28: 2345–51.
12. Mc Donald A, Eurich DT, Mayumidar SR.Treatment of type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case-Control Study From UK General Practice Research Datebase. Diabet Care 2010; 33: 1210–9.
13. Bowker SL, Veugelers P. Majumdar SR, Jonson JA. Increased Cancer-Related Mortalitt for Patients With Type 2 Diabetes Who Use Sulfanilureas or Insulin. Diabet Care 2006; 29: 254–8.
14. Currie CJ, Pool CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetology DOI:10. 1007/ s00125–009–1440–6.
15. Landman GWG, Kleefstra N, Van Haleren KJJ. Metformin associated with Lower Cancer Mortality in Type 2 Diabetes. Diabet Care 2010; 33: 322–6.
16. Берштейн Л.М. Гиполипидемические и антидиабетические препараты как средство предупреждения и терапии злокачественных опухолей: клинические данные. НИИ онкологии им. проф. Н.Н.Петрова МЗ РФ, Санкт-Петербург. Сборник тезисов VIII Российского онкологического конгресса. М., 22–24 ноября 2004 г.
Авторы
О.М.Смирнова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.